|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
|
|
2
|
Alexandrov LB, Nik-Zainal S, Wedge DC,
Campbell PJ and Stratton MR: Deciphering signatures of mutational
processes operative in human cancer. Cell Rep. 3:246–259. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bamford S, Dawson E, Forbes S, et al: The
COSMIC (Catalogue of Somatic Mutations in Cancer) database and
website. Br J Cancer. 91:355–358. 2004.PubMed/NCBI
|
|
4
|
Forbes SA, Bindal N, Bamford S, et al:
COSMIC: mining complete cancer genomes in the Catalogue of Somatic
Mutations in Cancer. Nucleic Acids Res. 39:D945–D950. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Alexandrov LB, Nik-Zainal S, Wedge DC, et
al; Australian Pancreatic Cancer Genome Initiative; ICGC Breast
Cancer Consortium; ICGC MMML-Seq Consortium; ICGC PedBrain.
Signatures of mutational processes in human cancer. Nature.
500:415–421. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
O’Hanlon LH: How next-generation
sequencing could change cancer care. J Natl Cancer Inst.
105:836–838. 2013.PubMed/NCBI
|
|
7
|
Rothberg JM, Hinz W, Rearick TM, et al: An
integrated semiconductor device enabling non-optical genome
sequencing. Nature. 475:348–352. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nishino M, Jackman DM, Hatabu H, et al:
New Response Evaluation Criteria in Solid Tumors (RECIST)
guidelines for advanced non-small cell lung cancer: comparison with
original RECIST and impact on assessment of tumor response to
targeted therapy. AJR Am J Roentgenol. 195:W221–W228. 2010.
View Article : Google Scholar
|
|
9
|
Schewe C, Goldmann T, Grosser M, et al:
Inter-laboratory validation of PCR-based detection of
Mycobacterium tuberculosis in formalin-fixed,
paraffin-embedded tissues. Virchows Arch. 447:573–585. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hadd AG, Houghton J, Choudhary A, et al:
Targeted, high-depth, next-generation sequencing of cancer genes in
formalin-fixed, paraffin-embedded and fine-needle aspiration tumor
specimens. J Mol Diagn. 15:234–247. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Quail MA, Smith M, Coupland P, et al: A
tale of three next generation sequencing platforms: comparison of
Ion Torrent, Pacific Biosciences and Illumina MiSeq sequencers. BMC
Genomics. 13:3412012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tejpar S, Celik I, Schlichting M,
Sartorius U, Bokemeyer C and Van Cutsem E: Association of KRAS G13D
tumor mutations with outcome in patients with metastatic colorectal
cancer treated with first-line chemotherapy with or without
cetuximab. J Clin Oncol. 30:3570–3577. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wu S, Gao Y, Dong X, et al: Serum
metabonomics coupled with Ingenuity Pathway Analysis characterizes
metabolic perturbations in response to hypothyroidism induced by
propylthiouracil in rats. J Pharm Biomed Anal. 72:109–114. 2013.
View Article : Google Scholar
|
|
14
|
Cho KH, Baek S and Sung MH: Wnt pathway
mutations selected by optimal beta-catenin signaling for
tumorigenesis. FEBS Lett. 580:3665–3670. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Engelman JA, Luo J and Cantley LC: The
evolution of phosphatidylinositol 3-kinases as regulators of growth
and metabolism. Nat Rev Genet. 7:606–619. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Vivanco I and Sawyers CL: The
phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang G and Yang X: Smad4-mediated TGF-beta
signaling in tumorigenesis. Int J Biol Sci. 6:1–8. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cancer Genome Atlas Network. Comprehensive
molecular characterization of human colon and rectal cancer.
Nature. 487:330–337. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chapman PB, Hauschild A, Robert C, et al;
BRIM-3 Study Group. Improved survival with vemurafenib in melanoma
with BRAF V600E mutation. N Engl J Med. 364:2507–2516. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lièvre A, Bachet JB, Le Corre D, et al:
KRAS mutation status is predictive of response to cetuximab therapy
in colorectal cancer. Cancer Res. 66:3992–3995. 2006.PubMed/NCBI
|
|
21
|
Okamoto K, Neureiter D, Alinger B, et al:
The dual EGF/VEGF receptor tyrosine kinase inhibitor AEE788
inhibits growth of human hepatocellular carcinoma xenografts in
nude mice. Int J Oncol. 33:733–742. 2008.PubMed/NCBI
|
|
22
|
Traxler P, Allegrini PR, Brandt R, et al:
AEE788: a dual family epidermal growth factor receptor/ErbB2 and
vascular endothelial growth factor receptor tyrosine kinase
inhibitor with antitumor and antiangiogenic activity. Cancer Res.
64:4931–4941. 2004. View Article : Google Scholar
|
|
23
|
Serra V, Markman B, Scaltriti M, et al:
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and
inhibits the growth of cancer cells with activating PI3K mutations.
Cancer Res. 68:8022–8030. 2008. View Article : Google Scholar : PubMed/NCBI
|
